A Scalable Synthesis of an Azabicyclooctanyl Derivative, a Novel DPP-4 Inhibitor

被引：23

作者：

Fei, Zhongbo ^{[2
]}

Wu, Quanbing ^{[2
]}

Zhang, Fei ^{[2
]}

Cao, Yudong ^{[2
]}

Liu, Chuanqin ^{[2
]}

Shieh, Wen-Chung ^{[1
]}

Xue, Song ^{[1
]}

McKenna, Joe ^{[1
]}

Prasad, Kapa ^{[1
]}

Prashad, Mahavir ^{[1
]}

Baeschlin, Daniel ^{[3
]}

Namoto, Kenji ^{[3
]}

机构：

[1] Novartis Pharmaceut, Chem & Analyt Dev, E Hanover, NJ 07936 USA

[2] Suzhou Novartis Pharma Technol Co Ltd, Chem & Analyt Dev, Changshu 215537, Jiangsu, Peoples R China

[3] Novartis Inst Biomed Res, Ctr Prote Chem, CH-4002 Basel, Switzerland

来源：

JOURNAL OF ORGANIC CHEMISTRY | 2008年 / 73卷 / 22期

关键词：

D O I：

10.1021/jo801830x

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A practical synthetic strategy to a chiral azabicycclooctanyl derivative (1), a potent DPP-4 inhibitor, starting from a commercially available nortropine is described. The stereogenic center of 1 was established employing a modified protocol of Ellman's diastereoselective addition of a benzylic nucleophile to tert-butanesulfinimme. Other key steps include Corey-Chaykovsky reaction, Meinwald rearrangement, and CDMT-promoted amide bond formation involving a sterically hindered amine 2.

引用

页码：9016 / 9021

页数：6

共 50 条

[41] A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats
Kimura, Shinichiro
Inoguchi, Toyoshi
Yamasaki, Toshihide
Yamato, Mayumi
Ide, Makoto
Sonoda, Noriyuki
Yamada, Kenichi
Takayanagi, Ryoichi
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (03): : 138 - 145
[42] Emodin derivatives as novel potent DPP-4 inhibitors: Design, synthesis, and in vitro evaluation
Masyita, Ayu
Firdayani, Firdayani
Listiana, Shelvi
Besari, Ariza Yandwiputra
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 735
[43] Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors
Kaczanowska, Katarzyna
Wiesmueller, Karl-Heinz
Schaffner, Arnaud-Pierre
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 530 - 535
[44] DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Eun Ju Bae
Archives of Pharmacal Research, 2016, 39 : 1114 - 1128
[45] Cardioprotective effects of dipeptidyl peptidase-4 (DPP-4) inhibitors independently of DPP-4
Yamaguchi, T.
Yasukatsu, I.
Yamazaki, T.
Nakamura, Y.
Shimada, K.
Yoshiyama, M.
Iwao, H.
EUROPEAN HEART JOURNAL, 2015, 36 : 777 - 777
[46] DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus
不详
FORMULARY, 2009, 44 (09) : 261 - 261
[47] DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, Eun Ju
ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (08) : 1114 - 1128
[48] Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1367): : 49 - 50
[49] Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes
Liu, Zhenhua
Xu, Lanting
Xing, Meimei
Xu, Xiaojie
Wei, Jinfeng
Wang, Jinmei
Kang, Wenyi
BIOMEDICINE & PHARMACOTHERAPY, 2020, 125
[50] Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Johnson, Kathryn M. S.
Schurr, Kathleen
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 81 - 92

← 1 2 3 4 5 →